Simona Cristea

Dana-Farber Cancer Institute
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (5)

Supplemental Table 7A: Clinical evaluation and characterisitcs of KPC mice treated until clinical endpoint. Supplemental Table 7B: Clinical evaluation and characterisitcs of KPC mice treated for 3 days.

Year:

2024

Supplemental Table 5A: Drug sensitivity metrics from MRTX1133-treated KRAS G12D patient-derived organoids. Supplemental Table 5B: MRTX1133 dose response across KRAS G12D mutated patient-derived organoids.

Year:

2024

Supplemental Figure 1: Acquired resistance to KRAS G12C inhibition in PDAC and other GI cancers. Supplemental Figure 2: MRTX1133 sensitivity across KRAS G12D mutant in vitro models of PDAC. Supplemental Figure 3: Isogenic models of acquired resistance to MRTX1133. Supplemental Figure 4: In vivo treatment and tumor monitoring for the KPC PDAC mouse model. Supplemental Figure 5: Genomic characterization of KPC tumors. Supplemental Figure 6: snRNA-seq quality metrics and description of the tumor microenvironment. Supplemental Figure 7: Identification and characterization of malignant cell populations. Supplemental Figure 8: Characterization of malignant metaprograms in KPC tumors. Supplemental Figure 9: Treatment with MRTX1133 induces modest changes in the immune microenvironment following tumor regression. Supplemental Figure 10: Treatment of 6694C2-LM tumors with MRTX1133 reduces granulocytes but has little effect on T cells. Supplemental Figure 11: Neoadjuvant and adjuvant therapy in a metastatic model of PDAC.

Year:

2024

KRAS inhibitors demonstrate clinical efficacy in pancreatic ductal adenocarcinoma (PDAC); however, resistance is common. Among patients with KRAS G12C -mutant PDAC treated with adagrasib or sotorasib, mutations in PIK3CA and KRAS , and amplifications of KRAS G12C , MYC , MET , EGFR , and CDK6 emerged at acquired resistance. In PDAC cell lines and organoid models treated with the KRAS G12D inhibitor MRTX1133, epithelial-to-mesenchymal transition and PI3K-AKT-mTOR signaling associate with resistance to therapy. MRTX1133 treatment of the Kras LSL-G12D/+ ; Trp53 LSL-R172H/+ ; p48- Cre (KPC) mouse model yielded deep tumor regressions, but drug resistance ultimately emerged, accompanied by amplifications of Kras , Yap1 , Myc , Cdk6, and Abcb1a/b , and co-evolution of drug-resistant transcriptional programs. Moreover, in KPC and PDX models, mesenchymal and basal-like cell states displayed increased response to KRAS inhibition compared to the classical state. Combination treatment with KRAS G12D inhibition and chemotherapy significantly improved tumor control in PDAC mouse models. Collectively, these data elucidate co-evolving resistance mechanisms to KRAS inhibition and support multiple combination therapy strategies. Significance: Acquired resistance may limit the impact of KRAS inhibition in patients with PDAC. Using clinical samples and multiple preclinical models, we define heterogeneous genetic and non-genetic mechanisms of resistance to KRAS inhibition that may guide combination therapy approaches to improve the efficacy and durability of these promising therapies for patients. See related commentary by Marasco and Misale, p. 2018

Year:

2024

Supplemental Table 4A: Differential gene expression analysis between MRTX1133 sensitive and resistant KRAS G12D cell lines. Supplemental Table 4B: Analysis of Copy number and RPPA datasets between MRTX1133 sensitive and resistant KRAS G12D cell lines.

Year:

2024

Collaborators (13)

Alexander Jordan

Assistant Professor

Yale University

UNITED STATES
View details

Stephanie Dougan

Associate Professor

Dana-Farber Cancer Institute

UNITED STATES
View details

Eliezer Van Allen

Professor

Harvard University

UNITED STATES
View details

Ben Stanger

University of Pennsylvania

UNITED STATES
View details

Peter Winter

Principal Investigator

Broad Institute

UNITED STATES
View details

Paola A. Guerrero

Research Group Leader

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Srivatsan Raghavan

Assistant Professor

Dana-Farber Cancer Institute

UNITED STATES
View details

David S. Hong

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Anirban Maitra

Laura and Isaac Perlmutter Professor of Pathology

NYU Langone Health

UNITED STATES
View details

Michael P. Kim

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Shubham Pant

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Alex K. Shalek

J. W. Kieckhefer Professor

Massachusetts Institute of Technology

UNITED STATES
View details

Jennifer Roth

Broad Institute

UNITED STATES
View details